Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract
Olatunji B. Alese(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Gabriel Sica(Emory University), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus), Francisco G. La Rosa(University of Colorado Anschutz Medical Campus), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), Michael R. Rossi(Sema4 (United States)), Bassel F. El‐Rayes(University of Alabama at Birmingham), Fadlo R. Khuri(American University of Beirut Medical Center), Dianne Alexis(Emory University), Guojing Zhang(Emory University)
Cited by 22
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|2005|1.6k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k